[Retracted] Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer

Table 2

Patient clinical efficacy assessment criteria.

Efficacy	Criteria
PD	Lesion growth ≥ 20%, or new lesions
SD	Lesion growth < 20%, or reduction of lesion volume < 30%, maintain time ≥ 30 d
PR	Lesion reduction ≥ 30%, maintain time ≥ 30 d
CR	The lesion disappeared completely, maintain time ≥ 30 d
ORR	(PR + CR)/58 × 100%
DCR	(SD + PR + CR)/58 × 100%

PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; ORR, overall response rate; DCR, disease control rate.